Mission of AABC

The mission of the Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the groups' areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Theresa Devins (tdevins@cogrx.com) or Dr. Ornit Chiba-Falek (ornit.chibafalek@clairigene.com), or Dr. Christopher Weber (cweber@alz.org), facilitator.

Welcome New Members

AABC is growing! Welcome to:

- **Marta Barrachina & Miguel Viribay, ADmit Therapeutics**
  ADmit Therapeutics is an innovative company based in Barcelona (Spain), and it is specialized in developing mitochondrial epigenetic-based diagnostic solutions for neurodegenerative diseases. Their mission is to advance the early diagnosis and prognosis of neurodegenerative diseases by developing cutting-edge AI-powered mitochondrial epigenetic analysis tools. ADmit Therapeutics has successfully developed a market-ready Alzheimer's disease classifier to determine the disease prognosis in mild cognitive impairment (MCI) patients accurately in the clinical setting. Based on pioneering research on neuroepigenetic mechanisms, especially in mitochondrial DNA (mtDNA), the company has developed the MAP-AD ß Test, the first predictive epigenetic test that provides the prognosis of progression from MCI to AD dementia, using a combination of Next-Generation Sequencing (NGS) and an AI/Supervised Machine Learning approach. The solution is a qualitative in vitro diagnostic (IVD) test comprising (1) a set of oligonucleotides intended for use by clinical laboratories and (2) medical software with the algorithm integrated intended for use by healthcare professionals. By analyzing mtDNA methylation patterns, MAP-AD® enables early and highly accurate identification of prodromal AD patients, including Aß-negative individuals in the basal visit but who subsequently convert to Aß positivity, often missed by conventional methods. As a cost-effective, minimally invasive alternative to PET imaging and cerebrospinal fluid analysis, it seamlessly integrates into existing clinical workflows, enhancing diagnostic accuracy and ensuring timely treatment decisions. Beyond patient care, allowing a properly triaging of patients candidates for the new monoclonal therapies, MAP-AD® delivers significant value to pharmaceutical companies by improving clinical trial stratification, reducing recruitment costs, and minimizing the risk of trial failures.
- **David Friend & Naaman Tammuz, Bitfount**
  Bitfount is an on-premise AI platform for patient pre-screening and research collaborations with a special focus on imaging and EHR data. Bitfount's no-code application automatically analyses imaging and EMR data on-premise using AI algorithms to evaluate inclusion/exclusion criteria for clinical trials and observational studies. Crucially, no data is ever transferred or seen by any third parties, including Bitfount. The desktop application also provides additional capabilities for AI model training and evaluation, all while preserving data privacy.
- **Subhanjan Mondal & Farooq Waheed, Sensify Inc.**
  Sensify Inc. develops real-world digital biomarker tools focused on early detection of neurodegenerative diseases through a multi-modal digital health platform. Their flagship product, ScentAware, is a digital olfactory testing system that leverages the fact that smell dysfunction appears 10-20 years before cognitive symptoms in diseases like Alzheimer's and Parkinson's. With their suite of digital sensory and cognitive assessment tools, Sensify aims to offer scalable early triage and population risk stratification for neurodegenerative diseases. Their technology platform enables recruitment of preclinical populations, supporting decentralized trials, and creating a pathway to demonstrate efficacy earlier in the disease process when interventions may be most effective.

AABC News

Alpha Cognition

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer's disease. This milestone marks a major step forward in the company's mission to provide innovative and accessible solutions for patients and caregivers — and to deliver new hope to the millions impacted by Alzheimer's. Read the full press release here.

Cognito Therapeutics

Cognito Therapeutics is a late-stage clinical neurotechnology company developing disease-modifying therapies for neurodegenerative diseases. Its lead product, Spectris™, is a non-invasive, at-home neuromodulation device designed to restore gamma brain wave activity disrupted in Alzheimer's disease. At the 2025 AD/PD™ conference, Cognito presented new data from its OVERTURE trial showing that Spectris preserved structural brain integrity in patients with mild-to-moderate Alzheimer's. Over six months, patients using Spectris daily maintained corpus callosum volume (+0.58%) compared to a decline in matched ADNI controls (-0.91%), a significant net difference of +1.49% ($p<0.004$). Spectris also induced robust 40 Hz gamma oscillations that correlated with MRI measures of brain health, including temporal lobe volume and occipital cortical thickness. With no observed ARIA, >80% adherence, and FDA Breakthrough Device Designation, Spectris is now being evaluated in HOPE, a pivotal trial enrolling 670 patients. Cognito's platform represents a potentially safer, scalable, and transformative approach to treating Alzheimer's disease.

Neuronascent

Neuronascent, Inc. has successfully completed 6-month GLP safety testing in rodents and dogs, and completed further GMP manufacturing of API to allow for the continued development of oral NNI-362 into Phase 2 for mild to moderate Alzheimer's disease. The Phase 1a was completed in aged individuals and a manuscript has been submitted for review/publication. This first-in-category, patented neuron regenerative therapy is separately utilizing GMP API for aged dogs with probable canine cognitive disorder, or CCD. This truly natural model of Alzheimer's disease, shares behavioral and physiologic aspects of the human disorder and through NNI-362 testing in dogs, Neuronascent should obtain results on a host of potential endpoints critical to both disorders. This proof-of-concept (POC) trial in aged dogs with CCD, assessing behavior, biomarkers and anosmia aims to be completed at a mere fraction of the time and cost of a POC Phase 2 Alzheimer's trial. Please contact BD head Josh Pan (jpan@neuronascent.com) if you would like to learn more about our unique NNI-362 disease-modifying therapy program, that takes a giant step forward aimed at halting CCD in dogs prior to halting disease progression in human AD patients.

Oasis Diagnostics

Oasis Diagnostics is hosting The Italian Saliva Symposium (ISS) a specialized conference that brings together professionals from the commercial sector and researchers from various fields to discuss advancements in salivary diagnostics and related technologies. Attendees will include pediatricians, dentists, physicians, diagnostic developers, researchers, CROs, pharmaceutical representatives and others. The event fosters collaboration across various disciplines including neurology, oral medicine, dentistry, pediatrics, oncology, the toxicology and hormone communities, general medicine and others while focusing on innovations and applications of the 'golden biofluid' saliva in diagnosis and prognosis of diseases where significant advances have been made.

The ISS features sessions on cutting-edge salivary technologies, educational opportunities (including continuing education credits), poster sessions, and networking platforms for the exchange of ideas and partnership development between the private sector and the research community. The symposium also showcases keynote speakers and presenters from around the globe, and roundtable discussions aimed at promoting the broader application of saliva in diagnostics and healthcare to the benefit of all patients. Registration will open soon and will be posted on our AABC LinkedIn. For any questions, please contact Paul Slowey (pds@4saliva.com).

Transpharmation

Transpharmation Ltd., a global leader in neuroscience, pain and metabolic disease preclinical contract research, is pleased to announce its acquisition of Saretius Ltd. (Saretius), a pioneering British company specializing in disease models and advanced biomarker development.

The acquisition of Saretius aligns with Transpharmation's vision to deliver groundbreaking translational biology for the human pharmaceutical and animal health drug disc.

Upcoming Scientific Meetings

AAIC Satellite Symposium
May 14-15, 2025 Lima, Peru and Online
AAIC Satellite Symposium aims to convene, support and strengthen the dementia science community in Latin America. This meeting is hosted in collaboration with the Global Brain Health Institute (GBHI) and the Atlantic Fellows for Equity in Brain Health.

AAIC 2025
Join us in Toronto, Canada and online July 27-31 for the Alzheimer's Association International Conference® 2025 (AAIC®). AAIC is the largest international meeting dedicated to advancing dementia science. Each year, AAIC convenes researchers, clinicians and dementia professionals from all career stages to share breaking research discoveries that will lead to improvements in diagnosis, risk reduction and treatments for Alzheimer's disease and other dementia. From basic science to dementia care, every aspect of the field's growing knowledge of dementia is incorporated into this world-class conference.

Registration is open.

All AABC members who exhibit at AAIC will be highlighted at the front of the hall.

Co-Chair Nominations

The AABC is now having a Call for Nominations for the co-chair position. Members are allowed to nominate someone or self-nominate. Nominees will be asked to provide a headshot, brief bio and statement of your interest in the role and how you may contribute to the overall mission of the AABC.

The new co-chair will replace Ornit Chiba-Falek. This position will serve with current co-chair Theresa Devins for two years beginning in July. Voting will take place in June, details will be provided with a list of candidates.

The co-chair responsibilities include:

Monthly calls with Alzheimer's Association staff Christopher Weber and Ashley Hansen to plan future events, propose new webinar topics, suggest speakers and discuss new directions.

Participate in webinars and in-person events.

Provide leadership and guidance on AABC topics and issues, as time allows.

If you are interested, please send us your name today to Ashley Hansen

Social Media

Follow our LinkedIn We look forward to using the page to foster partnerships and communications.

Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at (ahansen@alz.org).